RxDoctor Payments Data

Sunitha Bharadia, MD

Neurology with Special Qualifications in Child Neurology · Torrance, CANPI 1669447355

Payments from drug & device makers

$15,013in general payments, 2019–2025

Across 704 payments — averaging $21.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • UCB, Inc.$2K
  • Acadia Pharmaceuticals Inc$853
  • MDD US Operations, LLC$639
  • Merck$536
  • Neurocrine Biosciences, Inc.$530
  • plus $8K from 54 others

What the payments were for

  • Speaking & faculty fees$300%
  • Food & beverage$14,76898%
  • Education$2151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)160$2,764
UCB, Inc.78$1,789
Acadia Pharmaceuticals Inc45$853
MDD US Operations, LLC33$639
Merck22$536
Neurocrine Biosciences, Inc.16$530
EMD Serono, Inc.23$512
Lundbeck LLC19$481
Sanofi17$461
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)25$435
SK Life Science, Inc.15$395
Lilly USA, LLC15$375
Ipsen Biopharmaceuticals, Inc21$351
AstraZeneca(2 entities)12$329
Amgen13$316
Teva Pharmaceuticals USA, Inc.13$314
Jazz Pharmaceuticals Inc.6$311
Johnson & Johnson11$229
Neurelis, Inc.9$217
Takeda Pharmaceuticals U.S.A., Inc.8$200
Pfizer9$189
Biogen10$186
Novartis9$174
Otsuka America Pharmaceutical, Inc.7$168
Tanabe Pharma America, Inc.7$163
Abbott5$145
Aquestive Therapeutics, Inc.7$134
Sunovion Pharmaceuticals Inc.6$117
Avanir Pharmaceuticals, Inc.13$114
Kyowa Kirin, Inc.7$114
Amneal Pharmaceuticals LLC4$104
Eisai Inc.4$98
Biohaven Pharmaceuticals, Inc.4$96
Boston Scientific3$96
Alnylam Pharmaceuticals Inc.3$88
Merz Pharmaceuticals, LLC2$78
E.r. Squibb & Sons, L.L.C.5$77
CSL Behring3$74
Genentech USA, Inc.3$65
Banner Life Sciences, LLC3$60
Harmony Biosciences LLC3$59
Scpharmaceuticals Inc.2$57
GSK2$50
Biohaven Pharmaceutical Holding Company Ltd.2$42
Forte Bio-pharma LLC2$41
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$35
Boehringer Ingelheim1$32
Vanda Pharmaceuticals Inc.1$30
Corium, LLC1$29
Cranial Technologies, Inc2$28
Baxter Healthcare1$26
GE HealthCare1$24
Adamas Pharmaceuticals, Inc.1$23
Livanova USA, Inc.1$23
Otsuka Pharmaceutical Development & Commercialization, Inc.1$19
Medtronic1$18
Vertiflex, Inc.1$18
Medicomp Inc1$18
Aucta Pharmaceuticals, Inc.1$17
Metacel Pharmaceuticals LLC1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,013 in reported general payments places this provider in the 70th percentile of 216 neurology with special qualifications in child neurology providers in California.

See all neurology with special qualifications in child neurology providers in California

Medicare billing

Part B allowed, 2024
$135,365
Medicare patients
239
Services billed
3,545

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuedextaDextromethorphan Hbr/Quinidine76$110,502
IngrezzaValbenazine Tosylate12$88,444
Rivastigmine255$50,031
VraylarCariprazine Hcl32$48,802
XcopriCenobamate29$44,704
Tetrabenazine16$43,081
NeuproRotigotine31$35,917
RexultiBrexpiprazole15$19,256
NayzilamMidazolam15$12,945
RytaryCarbidopa/Levodopa15$11,856
NamzaricMemantine Hcl/Donepezil Hcl11$11,552
Pregabalin340$10,980
Memantine Hcl817$9,807
EliquisApixaban16$9,774
Entacapone88$8,533

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Avanir Pharmaceuticals, Inc.Nuedexta$114$110,50276 claims
Neurocrine Biosciences, Inc.Ingrezza$530$88,44412 claims
AbbVieVraylar, Namzaric$2,764$60,35443 claims
UCB, Inc.Neupro, Nayzilam$1,789$48,86246 claims
SK Life Science, Inc.Xcopri$395$44,70429 claims
Otsuka America Pharmaceutical, Inc.Rexulti$168$19,25615 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$104$13,29129 claims
PfizerEliquis$189$9,77416 claims
Lilly USA, LLCOlanzapine$375$4,065158 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 216 neurology with special qualifications in child neurology providers in California.

Other neurology with special qualifications in child neurology in Torrance

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →